<DOC>
	<DOC>NCT00339118</DOC>
	<brief_summary>The purpose of the study is achieve standardization treatment of low and intermediate risk rhabdomyosarcoma patients, with an attempt to improve treatment results in high and very high risk patients by the addition of doxorubicin as induction treatment and at the maintenance phase.</brief_summary>
	<brief_title>EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children</brief_title>
	<detailed_description />
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>child non metastatic rhabdomyosarcoma adequate heart, kidney, liver function age over 21 years, under 6 months metastatic disease heart, kidney, liver disease</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>June 2006</verification_date>
</DOC>